DifGen Pharmaceuticals LLC, a US-based specialty generic pharmaceutical company, announced on Thursday that its Canadian partner, Apotex Inc, has received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Nintedanib Soft Gel Capsules, 100 mg and 150 mg.
The product is therapeutically equivalent (AB-rated) to the reference listed drug, Ofev (nintedanib), which is indicated in adults for the treatment of idiopathic pulmonary fibrosis (IPF).
DifGen said that this approval represents a significant advancement in its expanding portfolio of complex generics.
BioArctic and Eisai report FDA extension of Leqembi Iqlik review
Mezzion reveals pre-IND FDA feedback on udenafil development in ADPKD
Altasciences and Certara form strategic partnership to accelerate early drug development
Xbrane resubmits FDA application for ranibizumab biosimilar after facility remediation
European Commission clears first pertuzumab biosimilar in Europe
Vanda Pharmaceuticals reports publication of imsidolimab phase III findings in NEJM Evidence
C-Ray Therapeutics' Copper-64 (Cu-64) Type II DMF gains FDA acceptance